Outrun Therapeutics
PrivateLast Round
Seed
Apr 18, 2024
Total Funding Raised
$10M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Outrun Therapeutics is a biotechnology company that develops small molecule inhibitors targeting E3 ligases for protein stabilization to treat diseases, with a lead program focused on hard-to-treat solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Outrun Therapeutics Comparables
Compare Outrun Therapeutics with similar companies based on industry and business-model similarity.
Outrun Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Apr 18, 2024 |
Outrun Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MP Healthcare Venture Management | Seed |
| M Ventures | Seed |
| M Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 17, 2026
Lead programme targets HPV positive head and neck cancer.
- Mar 17, 2026
Martin Scheffner joins the Scientific Advisory Board.
Outrun Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Outrun Therapeutics's valuation, stock price, and market status.